Incyte (INCY) news

Incyte Corp drops in volume surge, last down 3.0%

Incyte Corporation (INCY) shares declined 3.0% in afternoon trading on August 28, 2026, amid a notable surge in trading volume. The stock closed at $123.89, reflecting a pullback after a strong performance in recent months. Year-to-date, the stock has gained 25.43%, outperforming the S&P 500's…

Incyte: Canaccord Genuity initiates coverage with buy rating; price target $152

Incyte: Morgan Stanley raises target price to $119 from $104

Morgan Stanley has revised its price target for Incyte Corporation (INCY), raising it to $119 from $104, reflecting a positive outlook on the biopharmaceutical company’s near-term prospects. The updated target comes as INCY shares trade near the top of their 52-week range and above their 200-day…

Incyte outlook FY revenue USD 5,130-5,260 million

Incyte Corporation has provided an updated revenue outlook for fiscal year 2026, projecting total revenue in the range of USD 5,130 million to USD 5,260 million [1]. This guidance reflects the company’s current financial expectations based on its product performance and market conditions. The…

Incyte Q2 revenue USD 1,674 million vs. IBES estimate USD 1,474 million (corrects amount)

Incyte Corporation reported second-quarter revenue of $1,674 million, surpassing the IBES estimate of $1,474 million [1]. The results reflect strong performance across the company’s key therapeutic areas and highlight continued demand for its portfolio of prescription medicines. The revenue growth…